MIRA
INFORM REPORT
|
Report Date : |
07.01.2012 |
IDENTIFICATION DETAILS
|
Name : |
KOLON
PHARMACEUTICALS, INC. |
|
|
|
|
Registered Office : |
3rd Fl., Kolon Spotex Annex 1324-14, Seocho 2-dong, Seocho-gu, Seoul,
Korea 137-857 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
10.05.1958 |
|
|
|
|
Com. Reg. No.: |
214-81-13189 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Manufacture of Finished Medicaments |
|
|
|
|
No. of Employees : |
360 |
RATING & COMMENTS
|
MIRAs Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Exists |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Basic Information
|
Company
Name |
KOLON PHARMACEUTICALS,
INC. (Korean Company
Name : 코오롱제약(주)) |
|
Registered Address |
1324-14, Seocho 2-dong, Seocho-gu, Seoul,
Korea |
|
Building |
3rd Fl., Kolon Spotex Annex |
|
Zip Code |
137-857 |
|
Tel |
+82-2-580-6300 |
|
Fax |
+82-2-3473-0740 |
|
E-mail |
eunhasoo@kolon.com |
|
Website |
www.kolonpharm.co.kr |
|
Trading Address |
3rd Fl., Kolon Spotex Annex, 1324-14,
Seocho 2-dong, Seocho-gu, Seoul, Korea |
|
Tel |
+82-2-580-6300 |
|
Fax |
+82-2-3473-0740 |
|
Other Address-Daejeon Factory |
48-5, Munpyeong-dong, Daedeok-gu, Daejeon,
Korea |
|
Tel |
+82-42-930-5710 |
|
Fax |
+82-42-930-5777 |
|
Other Address-Gangnam Branch |
1680-3, Seocho-dong, Seocho-gu, Seoul, Korea |
|
Type |
Export |
|
Industry |
Manufacture of Finished Medicaments |
|
Main
Business |
Drugs & Pharmaceutical Products, Health Foods |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
10/05/1958 |
The Subject owns
the premises of Daejeon Factory.
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Cough and cold and antiallergy
products(51161800) |
|
Sell |
Antacids and antiflatulents(51171500) |
|
Sell |
Electrolytes(51191600) |
|
Sell |
Non narcotic analgesics and
antipyretics(51142000) |
|
Sell |
Thrombolytic drugs and platelet aggregation inhibitors(51131700) |
|
Sell |
Vasodilators(51122100) |
|
Sell |
Antibiotics(51101500) |
|
Sell |
Dietary supplements and nutritional therapy
products(51191900) |
|
Sell |
Drugs used for respiratory tract
disorders(51161700) |
|
Sell |
Laxatives(51171600) |
|
Sell |
Calcium salts and calcium
regulators(51182400) |
|
Sell |
Dental drugs(51212100) |
|
Sell |
Antiulcer and related gastrointestinal GI
drugs(51171900) |
|
Sell |
Antidiabetic agents and hyperglycemic
agents(51181500) |
|
Sell |
Laxatives(51171600) |
|
Sell |
Nonsteroidal anti inflammatory drugs
NSAIDs(51142100) |
|
Sell |
Urinary anti infectives and
analgesics(51102200) |
CEOs
|
Name |
Lee Woo-Sok |
|
Address |
Suite A-2103, 854, Jayang
4-dong, Gwangjin-gu, Seoul, Korea |
|
Date of Birth |
01/11/1957 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
6,000,000,000 |
||||||||||||
|
Employees |
360 |
||||||||||||
|
Formation |
Co., Ltd by shares A Company of Kolon Group |
||||||||||||
|
Bank Details |
Woori Bank- Mugyo Branch 45, Mugyo-Dong, Jung-Gu, Seoul 100-170
Korea Tel: +82-2-777-5871 Fax:+82-2-756-2960 |
||||||||||||
|
Corporate Registered No. |
110111-0256259 |
||||||||||||
|
Business Registered No. |
214-81-13189 |
||||||||||||
|
Permit & Licenses |
Intl Trade No.: 946016 |
||||||||||||
|
Shareholder Position |
|
||||||||||||
|
Company History |
10/05/1958 Incorporated as SAMYOUNG CHEMICAL RESEARCH CENTER CO., LTD. 1971 Changed company name to SAMYOUNG NEW DRUGS CO., LTD. 1979 Changed company name to SAMYOUNG NEW DRUGS CO., LTD. 07/01/1990 Changed company name to the present name 05/29/1996 Increased capital to 6,000,000,000 KRW from 4,060,000,000
KRW 03/20/1998 Increased the authorized shares to 3,200,000 shares from
1,600,000 shares 07/03/1998 Moved to the present HQ address from 1324-3, Seocho 2-dong,
Seocho-gu, Seoul, Korea |
||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Lee Woo-Sok |
Male |
Korean |
01/07/2008 |
|
Chairman |
Mr. |
Lee Woong-Yeol |
Male |
Korean |
03/02/1995 |
|
Director |
Mr. |
Eom Joon-Yong |
Male |
Korean |
03/23/2011 |
|
Auditor |
Mr. |
Yoon Kwang-Bok |
Male |
Korean |
12/28/2009 |
|
Supervisor of HQ Address |
Mr. |
Jung Joon-Ku |
Male |
Korean |
07/16/1979 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
76,363,861,422 |
76,001,377,419 |
6,637,359,685 |
|
|
2009 |
74,002,879,996 |
77,143,645,750 |
1,033,081,199 |
|
2008 |
62,839,236,649 |
64,792,024,266 |
797,579,818 |
|
2007 |
52,699,635,593 |
57,832,392,123 |
1,450,381,372 |
|
2006 |
48,221,695,356 |
55,289,660,958 |
1,101,049,093 |
Financial Description
|
Authorized Capital(KRW) |
16,000,000,000 |
|
Paid-Up Capital(KRW) |
6,000,000,000 |
|
Total Issued Shares |
1,200,000 |
Balance
Sheet
|
Unit :
Korean Won |
As of 12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Total Assets |
76,001,377,419 |
77,143,645,750 |
64,792,024,266 |
|
Current
Assets |
42,275,505,196 |
40,331,971,026 |
35,019,082,241 |
|
-Quick Assets |
36,147,519,883 |
34,478,766,900 |
30,467,582,755 |
|
-Inventories |
6,127,985,313 |
5,853,204,126 |
4,551,499,486 |
|
Fixed Assets |
33,725,872,223 |
36,811,674,724 |
29,772,942,025 |
|
-Investment |
3,380,805,129 |
8,190,515,498 |
7,060,992,263 |
|
-Tangibles |
18,861,324,417 |
18,346,523,069 |
13,282,230,722 |
|
-Intangibles |
5,325,649,274 |
4,221,293,344 |
3,180,499,293 |
|
-Others |
6,158,093,403 |
6,053,342,813 |
6,249,219,747 |
|
Total
Liabilities |
43,508,641,653 |
49,752,525,795 |
42,921,069,872 |
|
Current
Liabilities |
40,634,317,719 |
46,835,911,752 |
41,269,989,510 |
|
Fixed
Liabilities |
2,874,323,934 |
2,916,614,043 |
1,651,080,362 |
|
Capital
Stock |
6,000,000,000 |
6,000,000,000 |
6,000,000,000 |
|
Capital
Surplus |
4,328,190,514 |
4,328,190,514 |
4,328,190,514 |
|
Profit
Surplus |
18,121,098,479 |
11,483,738,794 |
10,450,657,595 |
|
Capital
Adjustment |
4,043,446,773 |
5,579,190,647 |
1,092,106,285 |
|
Total Equity |
32,492,735,766 |
27,391,119,955 |
21,870,954,394 |
|
Liab. &
Shareholders Equity |
76,001,377,419 |
77,143,645,750 |
64,792,024,266 |
|
Current
Liabilities |
40,634,317,719 |
46,835,911,752 |
41,269,989,510 |
|
Short-Term Borrowings |
30,000,000,000 |
36,000,000,000 |
35,614,867,522 |
|
Trade Payables |
3,727,672,666 |
3,797,855,580 |
1,840,112,614 |
|
Account Payables |
1,265,949,420 |
1,498,178,619 |
1,307,543,412 |
|
Withholdings |
316,926,702 |
580,411,531 |
262,624,059 |
|
Other Taxes Withhold |
95,082,220 |
64,685,291 |
50,262,530 |
|
VAT Withhold |
894,542,356 |
922,102,465 |
1,098,448,255 |
|
Accrued Income Tax |
3,451,436,393 |
1,471,775,361 |
1,039,686,915 |
|
Accrued Dividends |
2,952,450 |
2,952,450 |
4,297,250 |
|
Accrued Expenses |
47,147,845 |
277,336,520 |
52,146,953 |
|
Provisions for Refund |
832,607,667 |
220,613,935 |
- |
|
Current Portion of Debentures |
- |
2,000,000,000 |
- |
|
Fixed
Liabilities |
2,874,323,934 |
2,916,614,043 |
1,651,080,362 |
|
Provision for Severance & Retirement |
6,210,378,410 |
5,332,739,440 |
4,747,700,490 |
|
Deferred Income Tax Credit |
1,068,069,504 |
1,036,182,750 |
- |
Income
Statement
|
Unit : Korean Won |
As of 12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Sales |
76,363,861,422 |
74,002,879,996 |
62,839,236,649 |
|
Cost of Sold Goods |
26,742,018,603 |
27,501,226,474 |
19,927,623,446 |
|
Gross Profit |
49,621,842,819 |
46,501,653,522 |
42,911,613,203 |
|
Selling & Admin. Expenses |
46,620,130,431 |
40,906,883,566 |
36,446,705,248 |
|
Operating Income |
3,001,712,388 |
5,594,769,956 |
6,464,907,955 |
|
Non-Operating Income |
11,879,464,738 |
2,234,279,545 |
1,342,362,213 |
|
Non-Operating Expenses |
3,657,994,507 |
3,978,199,838 |
5,025,796,600 |
|
Income Before Taxes |
11,223,182,619 |
3,850,849,663 |
2,781,473,568 |
|
Income Taxes Expenses |
4,585,822,934 |
2,817,768,464 |
1,983,893,750 |
|
Net Income |
6,637,359,685 |
1,033,081,199 |
797,579,818 |
Cash
Flows
|
Unit :
Korean Won |
As of 12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Cash Flows
from Operating |
1,992,658,354 |
2,632,911,028 |
594,819,321 |
|
-Net Income |
6,637,359,685 |
1,033,081,199 |
797,579,818 |
|
-Exp. without
Cash Outflow |
7,461,332,351 |
6,441,634,622 |
6,252,287,935 |
|
-Revenue
without Cash Inflows |
-11,181,921,752 |
-1,605,174,837 |
-897,833,371 |
|
-Changes in
Asset/ & Liability |
-924,111,930 |
-3,236,629,956 |
-5,557,215,061 |
|
Cash Flows from
Investing |
8,601,592,603 |
-4,190,757,051 |
-7,460,535,314 |
|
-Cash Inflow
from Investing |
13,333,048,350 |
793,321,586 |
1,298,176,848 |
|
-Cash
Outflows for Investing |
-4,731,455,747 |
-4,984,078,637 |
-8,758,712,162 |
|
Cash Flows
from Financing |
-8,000,000,000 |
2,383,787,678 |
6,552,990,703 |
|
-Cash
Inflows from Financing |
9,000,000,000 |
20,827,415,442 |
57,913,629,927 |
|
-Cash
Outflows from Financing |
-17,000,000,000 |
-18,443,627,764 |
-51,360,639,224 |
|
Increase/Decrease
in Cash |
2,594,250,957 |
825,941,655 |
-312,725,290 |
|
Cash at the
Beginning of Year |
1,209,806,397 |
383,864,742 |
696,590,032 |
|
Cash at the
End of Year |
3,804,057,354 |
1,209,806,397 |
383,864,742 |
Products, Technologies, Services Description
|
Main Products & Services |
Drugs & Pharmaceutical Products, Health Foods |
Trade Partners & Competitors
|
Competitors |
DAEWOONG PHARMA CO., LTD.(134811-0075342) 223-23, SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO, KOREA TEL:+82-31-741-7700~4
FAX:+82-31-749-5535 ILDONG PHARMACEUTICAL CO., LTD(110111-0012776) 60, YANGJAE 1-DONG, SEOCHO-GU, SEOUL, KOREA TEL:+82-2-526-3114
FAX:+82-2-526-3030 DONGWHA PHARM IND CO., LTD.(110111-0043870) 5, SUNHWA-DONG, JUNG-GU, SEOUL, KOREA TEL:+82-2-2021-9300 FAX:+82-2-776-7873 |
Related Parties
(Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
KOLON CORPORATION(110111-0030528) KTP INDUSTRIES INC.(171311-0003504) KOLON FASHION CORPORATION(110111-2127292) NEOVIEWKOLON CO., LTD (134211-0040660) KF&T INDUSTRIES INC.(230111-0091824) KOLON PLASTICS INC.(171311-0003504) KOLON LIFE SCIENCE CO.,
LTD.(110111-1948277) CELLVIC DEVELOPMENT
CORPORATION(131111-0031292) CRYOTECH CO., LTD.(191211-0010226) KOLON FASHION MATERIAL INC.(135311-0011139) KOLON EVERAY CO., LTD.(176011-0054417) FNC KOLON CORP.(110111-0003973) KOLON BENIT CO.,
LTD.(135311-0003920) CAMBRIDGE MEMBERS CO., LTD.(134111-0000517) SWEET MEAL CO., LTD.(110111-2925604) SURPLUS GLOBAL, INC.(110111-1921140) KOLON MOTORS CO., LTD.(131111-0209708) KOLON ENGINEERING & CONSTRUCTION CO.,
LTD.(110111-0036502) KOLON CONSTRUCTION & CONSULTING CO.,
LTD.(170111-0230756) I PACIFIC PARTNERS INC.(110111-1902786) KOLON I' NETWORKS CORP.(110111-0712350) DEOK PYEONG LAND CO., LTD.(134411-0024149) KOLON ENVIRONMENTAL SERVICE CO.,
LTD.(135311-0005893) GREEN NARAE INC(161511-0078133) KESCO LANDSCAPE CO., LTD.(135311-0009572) KOLON BENIT CO., LTD.(135311-0003920) MAUNA OCEAN DEVELOPMENT CO.,
LTD.(171211-0045128) EFMC (ENVIRONMENTAL FACILITIES MANAGEMENT
CORPORATION 110111-1458739 ) ENVY SYSTEM INC.(110111-1028798) GREEN HWASUN INC.(160111-0199459) GREEN GYEONGSAN INC.(160111-0203622) GREEN SUNCHANG INC.(160111-0134942) ON ORGANICNANO ELECTROIC SYSEMS
INC.(200111-0255228) KOREA EPLATFORM CO., LTD.(110111-2008921) KOLON PLASTICS, INC.(171311-0003504) KOLON GLOTECH INC. (110111-0524838) (0.90% held by the subject company) KOLON WELLCARE CO., LTD.(110111-2930299) (49.37% held by the subject company) |
|
Corporate Ownership |
KOLON CORPORATION(110111-0030528) |
|
Major Shareholders |
KOLON CORPORATION(110111-0030528) |
|
Cooperative Enterprise |
-Insured Company SAMSUNG FIRE & MARINE INSURANCE CO., LTD.(110111-0005078) HYUNDAI MARINE & FIRE INSURANCECO., LTD.(110111-0035893) DONGBU INSURANCE CO., LTD.(110111-0095285) |
Sales by Region
(Activity &
Markets)
The Subject exports
to Pakistan, Singapore, Vietnam and Yemen.
Court Action
|
Case No. |
Court |
Plaintiff(s)/
Creditor(s)/ Applicant(s) |
Defendant(s)/ Debtor(s)/
Respondent(s) |
Cause |
Amount (Million KRW) |
Status |
|
|
|
National Health Insurance Corporation |
The Subject Company |
Claim for Compensation from Damages |
- |
5 cases are proceeding |
News Clipping
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.52.78 |
|
|
1 |
Rs.81.79 |
|
Euro |
1 |
Rs.67.46 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SCs credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.